Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050138 | 1.00 | KCNH2 (0.93) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| Ganaplacide SCHEMBL1047381 | 0.96 | KCNH2 (1.00) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL30718393 | 0.92 | KCNH2 (0.91) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL30718360 | 0.92 | KCNH2 (1.00) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL1051755 | 0.92 | KCNH2 (0.84) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL2068565 | 0.92 | KCNH2 (0.91) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL1049907 | 0.92 | KCNH2 (1.00) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL1051285 | 0.91 | KCNH2 (0.89) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 | |
| SCHEMBL15313630 | 0.91 | KCNH2 (0.85) | KCNH2CYP3A4TP53MAPTGAA | |
| SCHEMBL30718374 | 0.90 | KCNH2 (0.88) | KCNH2CYP3A4CYP1A2CYP2C9TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006970-A2 | ANTIMALARIAL COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2024006971-A2 | ANTIMALARIAL COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2024006970-A2 | ANTIMALARIAL COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006971-A2 | ANTIMALARIAL COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-04 | — | — | WO | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2013-10-24 | — | — | US | disclosed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, ABCB1, FDPS | KCNH2 1679/4885CYP3A4 97/4885CYP1A2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.